Under construction – not a live service
Sign in
Taking people in ChinaNo phase

Robotic Sleeve Lobectomy for Lung Cancer After Chemotherapy Plus Immunotherapy

Follows how well robotic lung surgery works in non-small cell lung cancer patients.

Key facts

Who runs it
Shanghai Chest Hospital
Where
Fuzhou, Guangzhou, Nanjing, Qingdao, Shanghai, Shenzhen, and Tianjing, ChinaSee the 7 sitesAlso in 2 other countries, 3 sites
Trial code
Registry title
RATS Sleeve Lobectomy After Neo-Chemo-IO for NSCLC
Status
Recruiting
People taking part
100 people, planned
Started
13 Apr 2026
Expected to end
30 May 2027
Type of study
Observational
Treatments tested
  • Robot-assisted thoracoscopic surgery (RATS) sleeve lobectomy
Record updated
21 April 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with non-small cell lung cancer who had chemotherapy plus immunotherapy before surgery and are planned for robotic sleeve lobectomy.

Age
18 years or older
Sex
All sexes can join
Disease stage
Non-small cell lung cancer, AJCC 9th clinical stage IIB-III, M0, judged resectable or potentially resectable by the multidisciplinary tumour team. ECOG performance status 0-2.
Earlier treatment
Planned neoadjuvant chemo-immunotherapy (PD-1/PD-L1 inhibitor + platinum doublet); extra chest radiotherapy is allowed. No earlier systemic therapy or chest radiotherapy for this cancer before the chemo-immunotherapy.

Main reasons for not taking part

  • Metastatic disease (M1) at baseline or at restaging
  • Neoadjuvant treatment with chemotherapy only, without immunotherapy
  • Clearly unresectable tumour at restaging, or the tumour team advises against surgery
  • Cannot have general anesthesia, or heart and lung risk is too high for surgery
  • Active autoimmune disease needing systemic immunosuppression within 2 years, prior organ transplant, or past grade 2 or higher pneumonitis/ILD

The registry criteria, word for word

Show all 17 criteriaShow less

Who can take part

  • Age ≥18 years
  • ECOG performance status 0-2
  • Histologically confirmed NSCLC
  • AJCC 9th clinical stage IIB-III, M0, deemed resectable or potentially resectable by the multidisciplinary tumour discussion (MDT)
  • Planned neoadjuvant chemo-immunotherapy (PD-1/PD-L1 inhibitor + platinum doublet；additional neoadjuvant thoracic radiotherapy is allowed)
  • Planned curative-intent RATS sleeve lobectomy with systematic nodal dissection
  • Baseline and restaging imaging per protocol (CT ± PET-CT)
  • Complete 30-day postoperative follow-up
  • Ability to provide informed consent

Who cannot take part

  • No immunotherapy component in neoadjuvant regimen (pure chemotherapy)
  • Prior systemic therapy or thoracic radiotherapy for the current cancer before starting chemo-IO
  • Palliative intent or planned non-anatomic resection only (e.g., wedge) when sleeve/lobectomy is indicated oncologically
  • Clear unresectability at restaging (e.g., multistation bulky N2/N3 not responding; unreconstructable T4 invasion) or MDT consensus against surgery
  • Active autoimmune disease requiring systemic immunosuppression within 2 years, prior organ transplant, or history of grade ≥2 pneumonitis/ILD
  • Metastatic disease (M1) at baseline or on restaging
  • Uncontrolled infection, pregnancy or breastfeeding, or any intercurrent illness that would compromise participation
  • Contraindication to general anesthesia or prohibitive cardiopulmonary risk precluding sleeve/lobectomy

Where in China

Also in 2 other countries, 3 sites

  • Fujian Medical University Union HospitalFuzhou, ChinaContact: Bin Zheng, MD, PhDTaking people
  • Guangdong Provincial People's HospitalGuangzhou, ChinaContact: Wenzhao Zhong, MD, PhDTaking people
  • Jiangsu Cancer Institute & HospitalNanjing, ChinaContact: Ming Li, MD, PhDTaking people
  • The Affiliated Hospital of Qingdao UniversityQingdao, ChinaContact: Wenjie Jiao, MD, PhDTaking people
  • Shanghai Chest Hospital, Shanghai Jiao Tong University Medicine of SchoolShanghai, ChinaContact: Zhigang Li, MD, PhDTaking people
  • Shenzhen People's HospitalShenzhen, ChinaContact: Guangsuo Wang, MD, PhDTaking people
  • Tianjin Medical University Cancer Institute & HospitalTianjing, ChinaContact: Jian You, MD, PhDTaking people

About the trial

What the trial wants to find out

The goal of this multicenter prospective observational study is to learn about the surgical difficulty and outcomes of robotic-assisted sleeve lobectomy in patients with non-small cell lung cancer (NSCLC) after neoadjuvant chemoimmunotherapy. The main questions it aims to answer are:

Read full original descriptionShow less

What is the rate of unsuccessful robotic-assisted sleeve lobectomy after neoadjuvant chemoimmunotherapy?

What factors are associated with unsuccessful surgery?

How do surgeons subjectively assess intraoperative difficulty across multiple dimensions during these procedures?

In this study, unsuccessful surgery is defined as any of the following: conversion to thoracotomy, incomplete (non-R0) resection, or major postoperative complications. Participants who are scheduled to undergo curative-intent robotic-assisted sleeve lobectomy as part of their routine clinical care after neoadjuvant chemoimmunotherapy will be enrolled from multiple centers. Clinical, intraoperative, pathological, and short-term postoperative data will be collected prospectively. In addition, surgeons will be asked to provide a multidimensional subjective assessment of intraoperative difficulty, including factors such as pleural adhesions, hilar fibrosis, nodal matting, fissure completeness, and vascular inflammation or edema, to better characterize the technical challenges of surgery and their association with perioperative outcomes.

The group in the trial

  • ⅡB-Ⅲ NSCLC following Neo-Chemo-IO & RATS sleeve lobectomy

    All patients in this cohort will receive neoadjuvant chemo-immunotherapy (Neo-Chemo-IO) first for clinical stage IIB-III non-small cell lung cancer ( NSCLC), followed by robot-assisted thoracoscopic surgery (RATS) sleeve lobectomy.

    Treatment: Robot-assisted thoracoscopic surgery (RATS) sleeve lobectomy

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
Robotic-Assisted Sleeve Lobectomy for Non-Small Cell Lung Cancer After Neoadjuvant Chemoimmunotherapy
Plain-language title
Robotic Sleeve Lobectomy for Lung Cancer After Chemotherapy Plus ImmunotherapyGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 13 November 2026.
Record updated
21 April 2026